Has Brian Borg, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,701,914 in general payments to Brian Borg, MD across 645 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Brian Borg, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Brian Borg, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Brian Borg, MD

Gastroenterology · Jackson, MSNPI 1902916778

Payments from drug & device makers

$1,701,914in general payments, 2019–2025

Across 645 payments — averaging $2638.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Intercept Pharmaceuticals, Inc.$616K
Gilead$287K
AbbVie$214K
Eli Lilly$167K
Bristol Myers Squibb$146K
Novartis$58K
plus $215K from 33 others

$25,676in research payments, 2019–2025

Across 42 payments — averaging $611.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Bausch Health US, LLC$17K
Eli Lilly$4K
Gilead$4K
AbbVie$1K

What the payments were for

Consulting fees$18,74528%
Speaking & faculty fees$29,86644%
Travel & lodging$5,7468%
Food & beverage$13,26020%
Education$900%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Intercept Pharmaceuticals, Inc.	128	$615,642
Gilead	140	$286,778
AbbVie(2 entities)	94	$213,678
Eli Lilly	22	$167,163
Bristol Myers Squibb	34	$146,378
Novartis	9	$57,629
GSK	13	$33,495
Novo Nordisk AS	11	$30,297
Alnylam Pharmaceuticals Inc.	14	$29,256
Madrigal Pharmaceuticals	40	$23,041
AstraZeneca(2 entities)	4	$16,874
Shire North American Group Inc	1	$15,000
Bausch Health US, LLC	4	$14,177
Intercept Pharma Europe Ltd.	2	$13,231
Amgen	4	$9,284
Dova Pharmaceuticals	2	$8,250
Pfizer	7	$6,955
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	30	$4,202
La Jolla Pharmaceutical Company	1	$4,000
Sanofi	4	$2,060
Johnson & Johnson	31	$778
Mirum Pharmaceuticals, Inc.	8	$624
Novo Nordisk	10	$603
Mallinckrodt Hospital Products Inc.	5	$575
Merck	1	$500
Boston Scientific	4	$392
Janssen Scientific Affairs, LLC	3	$308
Boehringer Ingelheim	2	$223
W. L. Gore & Associates, Inc.	1	$123
Ipsen Biopharmaceuticals, Inc	2	$120
Lilly USA, LLC	1	$68
Takeda Pharmaceuticals U.S.A., Inc.	2	$42
Ferring Pharmaceuticals Inc.	3	$40
Braintree Laboratories, Inc.	2	$34
Redhill Biopharma Inc.	2	$31
Albireo Pharma, Inc.	1	$18
Aimmune Therapeutics, Inc.	1	$18
Fujifilm Wako Diagnostics U.S.A. Corporation	1	$14
Evoke Pharma, Inc.	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

REZDIFFRA$18,896
OCALIVA$13,650
Livdelzi$5,336
XIFAXAN$3,602
DUPIXENT$1,767
CC-90001$610
TERLIVAZ$398
Livmarli$256
SPYGLASS$238
STELARA$210
Tremfya$142
RESMETIROM$133
AYVAKIT$130
XELJANZ$124
GORE VIATORR TIPS Endoprosthesis with Controlled Expansion$123
ORISE$118
IQIRVO$105

How this compares

$1,701,914 in reported general payments places this provider in the 95th percentile of 127 gastroenterology providers in Mississippi.

See all gastroenterology providers in Mississippi →

Medicare billing

Part B allowed, 2024

$38,342

Medicare patients

178

Services billed

339

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Ursodiol	17	$1,272
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl	15	$251

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Jackson

Mark WilsonJackson$191K
Thomas AmankonahJackson$84K
Shou Jiang TangJackson$72K
Pegah Hosseini-CarrollJackson$62K
David SchaeferJackson$29K
James WhatleyJackson$10K
Andrew WeeksJackson$10K
Stephen ChowJackson$9K
Praneeth BandaruJackson$9K
Reed HoganFlowood$761K

See the full list for Mississippi →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →